Cite

    Shoji, S. et al. (2022). Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain. British journal of clinical pharmacology. 88 (7), pp. 3321-3334. [Online].